\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand\HyperFirstAtBeginDocument{\AtBeginDocument}
\HyperFirstAtBeginDocument{\ifx\hyper@anchor\@undefined
\global\let\oldnewlabel\newlabel
\gdef\newlabel#1#2{\newlabelxx{#1}#2}
\gdef\newlabelxx#1#2#3#4#5#6{\oldnewlabel{#1}{{#2}{#3}}}
\AtEndDocument{\ifx\hyper@anchor\@undefined
\let\newlabel\oldnewlabel
\fi}
\fi}
\global\let\hyper@last\relax 
\gdef\HyperFirstAtBeginDocument#1{#1}
\providecommand\HyField@AuxAddToFields[1]{}
\providecommand\HyField@AuxAddToCoFields[2]{}
\citation{nichols2016psychedelics}
\citation{vollenweider2010serotonin}
\citation{rickli2016pharmacological}
\citation{carhart2016psilocybin,gasser2014safety}
\citation{kim2020structure,wacker2017crystal,mccorvie20195ht2c}
\@writefile{toc}{\contentsline {section}{\numberline {1}Introduction}{1}{section.1}\protected@file@percent }
\citation{eberhardt2021autodock}
\citation{rdkit}
\citation{meeko}
\citation{biopython}
\citation{oboyle2011openbabel}
\citation{eberhardt2021autodock}
\@writefile{toc}{\contentsline {section}{\numberline {2}Methods}{2}{section.2}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1}Compound Selection and Preparation}{2}{subsection.2.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.2}Receptor Structures and Preparation}{2}{subsection.2.2}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {1}{\ignorespaces Lysergamide compounds evaluated in this study.\relax }}{2}{table.caption.2}\protected@file@percent }
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{tab:molecules}{{1}{2}{Lysergamide compounds evaluated in this study.\relax }{table.caption.2}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2}{\ignorespaces Serotonin receptor structures used for docking.\relax }}{2}{table.caption.3}\protected@file@percent }
\newlabel{tab:receptors}{{2}{2}{Serotonin receptor structures used for docking.\relax }{table.caption.3}{}}
\citation{scipy}
\citation{hedlund2004serotonin}
\citation{brandt2017prodrug}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.3}Molecular Docking Protocol}{3}{subsection.2.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.4}Analysis and Visualization}{3}{subsection.2.4}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {3}Results}{3}{section.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1}Overall Binding Affinity Landscape}{3}{subsection.3.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2}LSD Receptor Selectivity Profile}{3}{subsection.3.2}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3}Comparative 5-HT\textsubscript  {2A} Binding}{3}{subsection.3.3}\protected@file@percent }
\citation{wacker2017crystal}
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces Heatmap of predicted binding affinities (kcal/mol) for eight lysergamide compounds across eleven serotonin receptor subtypes. More negative values (darker green/red) indicate stronger predicted binding. All 88 molecule--receptor combinations yielded converged docking results.\relax }}{4}{figure.caption.4}\protected@file@percent }
\newlabel{fig:heatmap}{{1}{4}{Heatmap of predicted binding affinities (kcal/mol) for eight lysergamide compounds across eleven serotonin receptor subtypes. More negative values (darker green/red) indicate stronger predicted binding. All 88 molecule--receptor combinations yielded converged docking results.\relax }{figure.caption.4}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces LSD binding affinity across all eleven serotonin receptor subtypes. The y-axis is inverted so that stronger binding (more negative affinity) appears higher. LSD binds all subtypes with affinities between $-7.4$ and $-9.8$\nobreakspace  {}kcal/mol.\relax }}{4}{figure.caption.5}\protected@file@percent }
\newlabel{fig:lsd_profile}{{2}{4}{LSD binding affinity across all eleven serotonin receptor subtypes. The y-axis is inverted so that stronger binding (more negative affinity) appears higher. LSD binds all subtypes with affinities between $-7.4$ and $-9.8$~kcal/mol.\relax }{figure.caption.5}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4}Structure--Activity Relationships}{4}{subsection.3.4}\protected@file@percent }
\citation{hedlund2004serotonin}
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces Comparison of predicted 5-HT\textsubscript  {2A} binding affinities across all eight lysergamide variants. ALD-52 and 1P-LSD show the strongest predicted binding, exceeding LSD itself.\relax }}{5}{figure.caption.6}\protected@file@percent }
\newlabel{fig:5ht2a_comparison}{{3}{5}{Comparison of predicted 5-HT\textsubscript {2A} binding affinities across all eight lysergamide variants. ALD-52 and 1P-LSD show the strongest predicted binding, exceeding LSD itself.\relax }{figure.caption.6}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.5}Receptor Selectivity Profiles}{5}{subsection.3.5}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces Structure--activity relationship: molecular weight vs.\ predicted 5-HT\textsubscript  {2A} binding affinity. The dashed line shows the linear regression ($R^2 = 0.535$, $p = 0.039$). Larger N-1 acylated derivatives (ALD-52, 1P-LSD) show enhanced binding.\relax }}{5}{figure.caption.7}\protected@file@percent }
\newlabel{fig:sar}{{4}{5}{Structure--activity relationship: molecular weight vs.\ predicted 5-HT\textsubscript {2A} binding affinity. The dashed line shows the linear regression ($R^2 = 0.535$, $p = 0.039$). Larger N-1 acylated derivatives (ALD-52, 1P-LSD) show enhanced binding.\relax }{figure.caption.7}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6}Cross-Validation with Alternative Structures}{5}{subsection.3.6}\protected@file@percent }
\citation{rickli2016pharmacological}
\citation{eberhardt2021autodock}
\citation{brandt2017prodrug}
\@writefile{lof}{\contentsline {figure}{\numberline {5}{\ignorespaces Radar plot comparing receptor selectivity profiles of LSD (red), ergine (blue), and ETH-LAD (green). Larger radius indicates stronger binding. All three share a broadly similar multi-receptor engagement pattern characteristic of the ergoline scaffold.\relax }}{6}{figure.caption.8}\protected@file@percent }
\newlabel{fig:radar}{{5}{6}{Radar plot comparing receptor selectivity profiles of LSD (red), ergine (blue), and ETH-LAD (green). Larger radius indicates stronger binding. All three share a broadly similar multi-receptor engagement pattern characteristic of the ergoline scaffold.\relax }{figure.caption.8}{}}
\@writefile{toc}{\contentsline {section}{\numberline {4}Discussion}{6}{section.4}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.1}Pharmacological Relevance}{6}{subsection.4.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.2}Structure--Activity Insights}{6}{subsection.4.2}\protected@file@percent }
\citation{katritch2013gpcr}
\@writefile{lof}{\contentsline {figure}{\numberline {6}{\ignorespaces Selectivity heatmap: binding affinity at each receptor subtype relative to the same molecule's 5-HT\textsubscript  {2A} affinity ($\Delta \Delta G$, kcal/mol). Blue indicates more selective binding at 5-HT\textsubscript  {2A}; red (negative values) indicates stronger binding at the alternative subtype. The 5-HT\textsubscript  {2A} column is zero by definition.\relax }}{7}{figure.caption.9}\protected@file@percent }
\newlabel{fig:selectivity}{{6}{7}{Selectivity heatmap: binding affinity at each receptor subtype relative to the same molecule's 5-HT\textsubscript {2A} affinity ($\Delta \Delta G$, kcal/mol). Blue indicates more selective binding at 5-HT\textsubscript {2A}; red (negative values) indicates stronger binding at the alternative subtype. The 5-HT\textsubscript {2A} column is zero by definition.\relax }{figure.caption.9}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.3}Limitations}{7}{subsection.4.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.4}Future Directions}{7}{subsection.4.4}\protected@file@percent }
\bibstyle{unsrtnat}
\bibcite{nichols2016psychedelics}{{1}{}{{}}{{}}}
\bibcite{vollenweider2010serotonin}{{2}{}{{}}{{}}}
\bibcite{rickli2016pharmacological}{{3}{}{{}}{{}}}
\bibcite{carhart2016psilocybin}{{4}{}{{}}{{}}}
\bibcite{gasser2014safety}{{5}{}{{}}{{}}}
\bibcite{kim2020structure}{{6}{}{{}}{{}}}
\@writefile{lof}{\contentsline {figure}{\numberline {7}{\ignorespaces Cross-validation: predicted affinities from primary structures (x-axis) vs.\ alternative PDB structures (y-axis) for all molecule--subtype pairs where both structures were available. The dashed line indicates perfect agreement ($y = x$). 5-HT\textsubscript  {2A} validation values are systematically weaker due to the lower-resolution cryo-EM structure.\relax }}{8}{figure.caption.10}\protected@file@percent }
\newlabel{fig:validation}{{7}{8}{Cross-validation: predicted affinities from primary structures (x-axis) vs.\ alternative PDB structures (y-axis) for all molecule--subtype pairs where both structures were available. The dashed line indicates perfect agreement ($y = x$). 5-HT\textsubscript {2A} validation values are systematically weaker due to the lower-resolution cryo-EM structure.\relax }{figure.caption.10}{}}
\@writefile{toc}{\contentsline {section}{\numberline {5}Conclusion}{8}{section.5}\protected@file@percent }
\bibcite{wacker2017crystal}{{7}{}{{}}{{}}}
\bibcite{mccorvie20195ht2c}{{8}{}{{}}{{}}}
\bibcite{eberhardt2021autodock}{{9}{}{{}}{{}}}
\bibcite{brandt2017prodrug}{{10}{}{{}}{{}}}
\bibcite{hedlund2004serotonin}{{11}{}{{}}{{}}}
\bibcite{rdkit}{{12}{}{{}}{{}}}
\bibcite{meeko}{{13}{}{{}}{{}}}
\bibcite{biopython}{{14}{}{{}}{{}}}
\bibcite{oboyle2011openbabel}{{15}{}{{}}{{}}}
\bibcite{scipy}{{16}{}{{}}{{}}}
\bibcite{katritch2013gpcr}{{17}{}{{}}{{}}}
\providecommand\NAT@force@numbers{}\NAT@force@numbers
\gdef \@abspage@last{9}
